The comparative safety of rosuvastatin: A retrospective matched cohort study in over 48000 initiators in statin therapy

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 7, 2006, Pages 444-453

  McAfee, Andrew T ^a,c   Ming, Eileen E ^b   Seeger, John D ^a   Quinn, Sherry G ^a   Ng, Eva W ^a   Danielson, Jared D ^a   Cutone, Jennifer A ^a   Fox, Jonathan C ^b,d   Walker, Alexander M ^a  

^a i3 Drug Safety   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hepatic dysfunction; Large administrative healthcare databases; Myopathy; Propensity scores; Renal dysfunction; Rhabdomyolysis; Rosuvastatin; Statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE GLOMERULONEPHRITIS; ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING DISORDER; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG FATALITY; DRUG SAFETY; DYSLIPIDEMIA; ENZYME DEFECT; FASCIA DISEASE; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HEALTH CARE COST; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEPATIC COMA; HEPATITIS; HEPATORENAL SYNDROME; HOSPITALIZATION; HUMAN; INCIDENCE; INFARCTION; ISCHEMIC HEART DISEASE; JAUNDICE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIGAMENT DISEASE; LIVER DYSFUNCTION; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; MYOSITIS; NEPHRITIS; NEPHROTIC SYNDROME; OLIGURIA; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RHABDOMYOLYSIS; RISK ASSESSMENT; TOXIC MYOPATHY; UNITED STATES; UREMIA;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; LIVER; MALE; MIDDLE AGED; MUSCULAR DISEASES; PYRIMIDINES; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; SAFETY; SULFONAMIDES;

EID: 33746655287     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1281     Document Type: Article

References (20)

1. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1(4): 495-505.
2. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87(5A): 2813-3213.
3. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003; 26(4 Suppl 3): III32-III38.
4. Ballantyne CM. Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol 2003; 92(4B): 3K-9K.
5. Cannon CP, Braunwald E, McCage CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
6. Topol EJ. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med 2004; 350(15): 1562-1564.
7. Expert Panel ATP-III. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239.
9. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346(7): 539-540.
10. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590.
11. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-572.
12. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-569.
13. Brewer HB, Jr.Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92(4B): 23K-29K.
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
15. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996; 276: 889-897.
16. Ayanian JZ, Landrum MB, Guadagnoli E, Gaccione P. Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction. N Engl J Med 2002; 347: 1678-1686.
17. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003; 92: 1447-1451.
18. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. PD Safe 2005; 14(7): 465-476.
19. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390-400.
20. Parsons LS. Reducing bias in a propensity-score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-sixth Annual SAS Users Group International Conference, Cary, NC: SAS Institute Inc. 2001; 214-226.